PFE Pfizer

Pfizer Inc.
Company
Patents are sorted by USPTO publication date, most recent first
APP
Utility
SGLT-2 Inhibitors for Treating Metabolic Disorders In Patients with Renal Impairment or Chronic Kidney Disease
24 Sep 20
The present invention relates to certain SGLT-2 inhibitors, such as ertugliflozin or a co-crystal or a pharmaceutically acceptable salt thereof, for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).
Ramachandra G. Naik, Elizabeth S. Ommen, James Michael Rusnak, Steven G. Terra
Filed: 4 Jun 20
APP
Utility
Treatment of Abnormal Visceral Fat Deposition Using Soluble Fibroblast Growth Factor Receptor 3 (SFGFR3) Polypeptides
24 Sep 20
The invention features methods of using SFGFR3 polypeptides to treat abnormal visceral fat deposition and the conditions associated with abnormal visceral fat deposition.
Elvire Gouze, Stéphanie Garcia
Filed: 20 Sep 18
GRANT
Utility
Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
22 Sep 20
Bing Wang, Daniel Chu
Filed: 13 Dec 19
GRANT
Utility
Process for preparing pneumococcal polysaccharide-protein conjugates
22 Sep 20
An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described.
William P. Hausdorff, George Rainer Siber, Peter R. Paradiso
Filed: 7 May 18
GRANT
Utility
Compositions relating to a mutant
15 Sep 20
In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B.
Kathrin Ute Jansen, Annaliesa Sybil Anderson, Robert G. K. Donald, Maninder K. Sidhu, Narender K. Kalyan, Justin Keith Moran, Mark E. Ruppen, Michael James Flint
Filed: 12 Jul 17
APP
Utility
Antibodies and Antibody-drug Conjugates Specific for CD123 and Uses Thereof
10 Sep 20
The present invention provides antibodies that specifically bind to CD123.
Manoj Baburao CHARATI, Yoon-Chi HAN, Madan KATRAGADDA, Nicole Melissa PICHÉ-NICHOLAS, Lawrence Nathan TUMEY
Filed: 16 Oct 18
APP
Utility
Heteroaromatic Compounds and Their Use As Dopamine D1 Ligands
10 Sep 20
Michael Aaron Brodney, Jennifer Elizabeth Davoren, Amy Beth Dounay, Ivan Viktorovich Efremov, David Lawrence Firman Gray, Michael Eric Green, Jaclyn Louise Henderson, Chewah Lee, Scot Richard Mente, Steven Victor O'Neil, Bruce Nelsen Rogers, Lei Zhang
Filed: 21 May 20
GRANT
Utility
Cyclin dependent kinase inhibitors
8 Sep 20
Ping Chen, Sujin Cho-Schultz, Judith Gail Deal, Gary Michael Gallego, Mehran Jalaie, Robert Steven Kania, Sajiv Krishnan Nair, Sacha Ninkovic, Suvi Tuula Marjukka Orr, Cynthia Louise Palmer
Filed: 23 Apr 19
APP
Utility
Antagonist Antibodies Against GDF-8 and Uses Therefor
3 Sep 20
The disclosure provides improved neutralizing anti-GDF-8 antibodies capable of substantially higher levels of expression in host cells compared to previous anti-GDF-8 antibodies.
MICHELLE M. MADER, JAMES R. APGAR, KEVIN D. PARRIS
Filed: 13 Nov 19
APP
Utility
EZH2 Inhibitor Combination Therapies
27 Aug 20
This invention relates to combination therapies comprising an EZH2 inhibitor and a chemotherapeutic agent, and associated pharmaceutical compositions, methods of treatment, and pharmaceutical uses.
Manfred Kraus, Pei-Pei Kung, Thomas Andrew Paul, Shikhar Sharma, Dominique Verhelle
Filed: 9 Nov 18
GRANT
Utility
Immunogenic compositions and uses thereof
25 Aug 20
The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant.
Annaliesa Sybil Anderson, Leena Shriram Bagle, Amardeep Singh Bhupender Bhalla, Miguel Angel Garcia, Lei Hu, Lakshmi Khandke, Avvari Krishna Prasad, Cindy Xudong Yang
Filed: 1 Nov 17
APP
Utility
Therapeutic Particles with Peptide Boronic Acid or Boronate Ester Compounds and Methods of Making and Using Same
20 Aug 20
Disclosed herein are compositions for treating and preventing diseases such as myeloma and lymphoma, where the compositions include a biocompatible, therapeutic polymeric nanoparticle having a boronate ester compound or a peptide boronic acid compound, and a biodegradable polymer.
Mir Mukkaram Ali, Maria Conceicao Figueiredo, Jeffrey Hrkach, Young-Ho Song, James Wright, Stephen E. Zale
Filed: 19 Oct 17
APP
Utility
Dihydropyridophthalazinone Inhibitors of Poly(adp-ribose)polymerase (Parp)
20 Aug 20
Bing WANG, Daniel CHU
Filed: 13 Dec 19
APP
Utility
Recombinant Vaccinia Virus and Methods of Use Thereof
20 Aug 20
The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus, compositions comprising the vaccinia virus, and use of the vaccinia virus or composition for inducing oncolysis in an individual having a tumor.
David H. Kirn, Liliana Maruri Avidal, Prajit Limsirichai
Filed: 10 Feb 20
APP
Utility
Dihydro-pyrrolo-pyridine Derivatives
20 Aug 20
Elizabeth Mary Beck, Michael Aaron Brodney, Matthew Frank Brown, Christopher Ryan Butler, Adam Matthew Gilbert, Erik Alphie Lachapelle, Laura Ann McAllister, Daniel Paul Uccello, Lei Zhang
Filed: 14 Jun 18
GRANT
Utility
Glycoconjugation process
18 Aug 20
The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.
Mingming Han, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad
Filed: 9 Jul 19
APP
Utility
Compositions and Methods for Eliciting an Immune Response Against Clostridium Difficile
13 Aug 20
In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof.
Kathrin Ute Jansen, Annaliesa Sybil Anderson, Robert G.K. Donald, Michael James Flint, Nicholas Randolph Everard Kitchin, Justin Keith Moran, Louise Pedneault, Michael W. Pride, Mark Edward Ruppen, Christopher Frederick Webber
Filed: 14 Sep 18
APP
Utility
GLP-1 Receptor Agonists and Uses Thereof
13 Aug 20
Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
Gary Erik Aspnes, Scott W. Bagley, John M. Curto, Matthew S. Dowling, David Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Gajendra Ingle, Wenhua Jiao, Chris Limberakis, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
Filed: 29 Apr 20
APP
Utility
Combination of a PARP Inhibitor and a PD-1 Axis Binding Antagonist
13 Aug 20
This invention relates to a method of treating cancer by administering a PARP inhibitor in combination with a PD-1 axis binding antagonist to a patient in need thereof.
John Andrew Blake-Haskins, Christoffel Hendrik Boshoff, Rossano Cesari, Dimitry Serge Antoine Nuyten, Ross Anthony Stewart, Fabian Zohren
Filed: 10 Oct 18
GRANT
Utility
6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
11 Aug 20
Thomas Allen Chappie, Nandini Chaturbhai Patel, Patrick Robert Verhoest, Christopher John Helal, Simone Sciabola, Erik Alphie LaChapelle, Travis T. Wager, Matthew Merrill Hayward
Filed: 31 May 19